The outstanding performance of O3-type NaNi_(1/3)Fe_(1/3)Mn_(1/3)O_(2)(NFM111)at both high and low temperatures coupled with its impressive specific capacity makes it an excellent cathode material for sodium-ion batte...The outstanding performance of O3-type NaNi_(1/3)Fe_(1/3)Mn_(1/3)O_(2)(NFM111)at both high and low temperatures coupled with its impressive specific capacity makes it an excellent cathode material for sodium-ion batteries.However,its poor cycling,owing to highpressure phase transitions,is one of its disadvantages.In this study,Cu/Ti was introduced into NFM111 cathode material using a solidphase method.Through both theoretically and experimentally,this study found that Cu doping provides a higher redox potential in NFM111,improving its reversible capacity and charge compensation process.The introduction of Ti would enhance the cycling stability of the material,smooth its charge and discharge curves,and suppress its high-voltage phase transitions.Accordingly,the NaNi_(0.27)Fe_(0.28)Mn_(0.33)Cu_(0.05)Ti_(0.06)O_(2)sample used in the study exhibited a remarkable rate performance of 142.97 mAh·g^(-1)at 0.1 C(2.0-4.2 V)and an excellent capacity retention of 72.81%after 300 cycles at 1C(1C=150 mA·g^(-1)).展开更多
目的基于网状meta分析口服中成药联合西药治疗冠心病合并高脂血症的有效性和安全性。方法运用计算机检索中国知网(CNKI)、万方数据(WANFANG DATA)、维普(VIP)、SinoMed、PubMed、Web of Science、Cochrane Library数据库中2019年1月—2...目的基于网状meta分析口服中成药联合西药治疗冠心病合并高脂血症的有效性和安全性。方法运用计算机检索中国知网(CNKI)、万方数据(WANFANG DATA)、维普(VIP)、SinoMed、PubMed、Web of Science、Cochrane Library数据库中2019年1月—2023年12月所有的口服中成药联合西药治疗冠心病合并高脂血症的临床随机试验(randomized controlled trial,RCT),将检索到的文献进行筛选,确定最终纳入文献并提取数据,用Stata 14、Revman 5.4进行统计分析。结果纳入56篇RCTs,共5080例患者,包括16种口服中成药。根据网状meta分析显示,在临床有效率方面,累积排名曲线下面积(surface under the cumulative ranking curve,SUCRA)概率排位前3为脂必泰、延丹胶囊、通心络胶囊;在甘油三酯方面,SUCRA概率排序前3为冠心宁片、心可舒胶囊、麝香保心丸;在总胆固醇方面,SUCRA概率排序前3为冠心宁片、心可舒胶囊、脂必妥;在低密度脂蛋白胆固醇方面,SUCRA概率排序前3为冠心宁片、脂必妥、心可舒胶囊;在高密度脂蛋白胆固醇方面,SUCRA概率排序前3为麝香保心丸、脂必妥、冠心宁片;在左心室射血分数方面,SUCRA概率排序前3为通心络胶囊、复方丹参滴丸、麝香保心丸。结论口服中成药联合西药治疗冠心病合并高脂血症的疗效优于单独西药治疗。展开更多
基金supported by the Low-Cost Long-Life Batteries program,China(No.WL-24-08-01)the National Natural Science Foundation of China(No.22279007)。
文摘The outstanding performance of O3-type NaNi_(1/3)Fe_(1/3)Mn_(1/3)O_(2)(NFM111)at both high and low temperatures coupled with its impressive specific capacity makes it an excellent cathode material for sodium-ion batteries.However,its poor cycling,owing to highpressure phase transitions,is one of its disadvantages.In this study,Cu/Ti was introduced into NFM111 cathode material using a solidphase method.Through both theoretically and experimentally,this study found that Cu doping provides a higher redox potential in NFM111,improving its reversible capacity and charge compensation process.The introduction of Ti would enhance the cycling stability of the material,smooth its charge and discharge curves,and suppress its high-voltage phase transitions.Accordingly,the NaNi_(0.27)Fe_(0.28)Mn_(0.33)Cu_(0.05)Ti_(0.06)O_(2)sample used in the study exhibited a remarkable rate performance of 142.97 mAh·g^(-1)at 0.1 C(2.0-4.2 V)and an excellent capacity retention of 72.81%after 300 cycles at 1C(1C=150 mA·g^(-1)).
文摘目的基于网状meta分析口服中成药联合西药治疗冠心病合并高脂血症的有效性和安全性。方法运用计算机检索中国知网(CNKI)、万方数据(WANFANG DATA)、维普(VIP)、SinoMed、PubMed、Web of Science、Cochrane Library数据库中2019年1月—2023年12月所有的口服中成药联合西药治疗冠心病合并高脂血症的临床随机试验(randomized controlled trial,RCT),将检索到的文献进行筛选,确定最终纳入文献并提取数据,用Stata 14、Revman 5.4进行统计分析。结果纳入56篇RCTs,共5080例患者,包括16种口服中成药。根据网状meta分析显示,在临床有效率方面,累积排名曲线下面积(surface under the cumulative ranking curve,SUCRA)概率排位前3为脂必泰、延丹胶囊、通心络胶囊;在甘油三酯方面,SUCRA概率排序前3为冠心宁片、心可舒胶囊、麝香保心丸;在总胆固醇方面,SUCRA概率排序前3为冠心宁片、心可舒胶囊、脂必妥;在低密度脂蛋白胆固醇方面,SUCRA概率排序前3为冠心宁片、脂必妥、心可舒胶囊;在高密度脂蛋白胆固醇方面,SUCRA概率排序前3为麝香保心丸、脂必妥、冠心宁片;在左心室射血分数方面,SUCRA概率排序前3为通心络胶囊、复方丹参滴丸、麝香保心丸。结论口服中成药联合西药治疗冠心病合并高脂血症的疗效优于单独西药治疗。
